🔗 Share this article

While the US undertakes unprecedented adjustments to its immunization guidelines, a particular individual has surfaced in a surprising turn: Høeg, a US-based sports medicine doctor and epidemiologist who rose to prominence by expressing skepticism about Covid shots in the global health crisis and has focused upon possible fatalities following COVID-19 vaccination in her recent position at the Food and Drug Administration.

Planned Overhauls to Pediatric Immunization Program

Public health authorities planned to announce major changes to the pediatric immunization program in December, aligning the US with Denmark’s immunization schedule, according to reports – a significant shift that would put the US out of step with much of the international standard with insufficient data for benefit. The announcement has been delayed until the next year.

In place of the top vaccines chief, Dr. Høeg is set to present at the gathering. She was recently named temporary leader of the FDA’s CDER, the fifth person to lead the office this year.

A New Direction at the FDA

This interim role might represent a tighter collaboration between the pharmaceutical and biologics divisions as Høeg and Prasad solidify control at the FDA – and it points to a renewed priority upon reevaluating already-approved vaccines at the FDA.

The new acting director has repeatedly called for ending specific childhood vaccine recommendations in the US in order to be more in line with the Danish model, a nation with universal health coverage and a citizenry approximately the population of Wisconsin’s.

So far statements, she has persisted in emphasizing on vaccination policy – traditionally the purview of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Questions Over Qualifications

Høeg has no obvious background in medication creation, regulation or management, which has been typical for former directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the FDA chief and the vaccine center since earlier this year.

“She appears not to have any of the qualifications” for leading the drug-regulation department, said Dr. Jonathan Howard. “She has not conducted a scientific study. She lacks experience in running a major agency. She lacks background in industry regulation.”

Former heads of the center would “understand legal statutes and the science of medication creation”, said Janet Woodcock. “Frankly, she lacks the sort of resume that former directors who ran CBER have had.”

CDER has an enormous workload at the FDA, the former commissioner pointed out.

“Everybody just focuses on the new drug program, but the off-patent medication office authorizes numerous generic drugs. There’s a biosimilars division, over-the-counter program and other areas, and every single one need to be looked after,” she explained. “The thing you overlook, that’s the thing that I always told people is going to cause problems.”

There is also, a major management aspect to the role, which manages over 5,000 personnel. “It is a massive administrative position, if you do it right,” she added.

Official Statement and Disputed Programs

Regarding concerns about Høeg’s fitness for the role and whether this assignment represents greater collaboration among regulatory chiefs on vaccines, a spokesperson stated that the “concerns rely on inaccurate premises”.

“Her experience aligns with the responsibilities of her role,” the official explained, citing the period Dr. Høeg spent counseling the agency head on “pharmaceutical safety and approval science, including computerized risk analysis and immunization monitoring”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's controversial expedited review system, a disputed one-day medication authorization process that apparently concerned her former heads. “How are these drugs being chosen for this voucher program? Who takes the calls?” Dr. Howard questioned. “There is a lot of lack of transparency going on at the regulatory body right now.”

Broadly speaking, he stated, “the FDA seems to be moving towards less stringent oversight of pharmaceuticals, except for shots.”

Public History on Vaccines

Regarding vaccines, Høeg has a more established, if concerning, past, Howard said. She published a research paper using unverified crowd-sourced reports to assess the rate of heart inflammation following COVID-19 immunization. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have changed statistics to indicate COVID-19 vaccinations are pose a greater threat than they are.

Among her “wish list” for the current federal leadership featured revising guidelines for recently developed shots and discontinuing “unnecessary” immunizations, she remarked post-election on a podcast. At the FDA, Høeg has allegedly proposed excluding teenage boys from getting COVID-19 vaccinations.

“She’s an all-around true believer who starts off with her beliefs and reverse-engineers to accommodate the evidence in a extremely misleading, dishonest fashion,” Howard said.

Gaining Influence and a “Revenge Tour”

Høeg joined other dissenters, {like|